Ine to end of remedy applying the final observation carried forward approach); and in sufferers with and without the need of baseline sexual dysfunction. CSFQ subscales evaluated 5 domains and 3 phases of sexual function plus satisfaction: pleasure, desire/frequency, desire/interest, arousal, and orgasm. CSFQ total scores range from 14 to 70, with baseline sexual dysfunction defined as CSFQ total score up to 47 for male sufferers and up to 41 for female individuals (Clayton et al., 1997). Sexual dysfunction during double-blind treatment was defined as CSFQ scores up to 47 (males) or as much as 41 (women) for no less than two consecutive visits throughout double-blind remedy. Posthoc benefits have been reported working with descriptive statistics; no inferential statistical analyses were performed.Adverse events connected to sexual functionThe number and percentage of adverse events (AEs) connected to sexual function have been reported by the preferred term for the safety population (all randomized individuals who received at least one dose of double-blind remedy).218 International Clinical Psychopharmacology 2015, Vol 30 NoTablePatient demographics and baseline CSFQ scores (CSFQ analysis population)Placebo (n = 264) Vilazodone 20 mg/day (n = 267) 42.1 (12.six) 56.9 73.0 31.four 38.5 46.8 64.5 53.9 Vilazodone 40 mg/day (n = 259) 41.0 (13.3) 57.1 70.7 31.1 37.two 46.5 69.6 55.0 Citalopram 40 mg/day (n = 257) 42.9 (12.five) 57.6 65.eight 31.2 37.3 46.4 66.9 52.Age [mean (SD)] (years) Ladies ( ) White ( ) MADRS total score (mean) CSFQ total score (imply) Women Males Sexual dysfunction ( )a Ladies Men42.0 (13.0) 55.7 69.three 31.two 38.1 46.4 61.9 50.CSFQ, Changes in Sexual Functioning Questionnaire; MADRS, Montgomery��sberg Depression Rating Scale. a Sexual dysfunction at baseline was defined as CSFQ total score 41 (ladies) or 47 (males) (Clayton et al., 1997).Fig.(a) Females 42 41 Imply CSFQ total score 40 39 38 37 36 35 Baseline Week four Week eight Week ten Placebo Vilazodone 20 mg/day Vilazodone 40 mg/day Citalopram 40 mg/day(b) Guys 51 50 Mean CSFQ total score 49 48 47 46 45 44 Baseline Week 4 Week 8 Week 10 Placebo Vilazodone 20 mg/day Vilazodone 40 mg/day Citalopram 40 mg/dayCSFQ scores by week in females (a) and men (b). CSFQ, Changes in Sexual Functioning Questionnaire.ResultsPatient demographicsCSFQ total score modifications in MADRS responders and nonrespondersThe CSFQ evaluation population comprised 1047 individuals (Table 1).AICAR Technical Information Baseline demographic qualities had been comparable among treatment groups; mean baseline CSFQ total scores had been 38 for girls and 46 for guys.Z-VEID-FMK manufacturer Far more than half with the sufferers had baseline sexual dysfunction, with prevalence higher for women than men, but comparable across remedy groups.PMID:23614016 CSFQ total score alterations in women and menIn all therapy groups, CSFQ total score elevated from baseline to week 10 for both ladies and men (Fig. 1). In ladies, imply change from baseline in CSFQ total score was 2.0 for placebo, 1.9 for vilazodone 20 mg/day, 3.0 for vilazodone 40 mg/day, and 1.two for citalopram. In males, imply modify from baseline was three.5 for placebo, 2.4 for vilazodone 20 mg/day, 1.two for vilazodone 40 mg/day, and 2.1 for citalopram.Inside the CSFQ analysis population, 50.four of placebo individuals, 64.1 of vilazodone 20 mg/day, 64.six of vilazodone 40 mg/day, and 62.9 of citalopram sufferers met the criteria for MADRS response (50 improvement from baseline) at the finish of double-blind treatment. For all therapy groups, MADRS responders and nonresponders had comparable baseline CSFQ total scores (Table 2). General,.